Andrew Moshfeghi, MD
Ophthalmology · Los Angeles, CANPI 1205859121
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.4%), ownership interests and grants — rather than concentrated in one kind of arrangement. Ocular Therapeutix, Inc. accounts for 86.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $300,208 and has fallen 85.4% since, to $43,961 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $4325.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$770K
- AbbVie$30K
- Regeneron Healthcare Solutions, Inc.$22K
- Regeneron$21K
- Novartis$11K
- Alcon Research LLC$11K
- plus $30K from 13 others
Across 47 payments — averaging $3306.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$65K
- Regeneron$63K
- Genentech, Inc.$17K
- F. Hoffmann-la Roche AG$10K
What the payments were for
- Consulting fees$415,24446%
- Speaking & faculty fees$97,13111%
- Grants$105,00012%
- Travel & lodging$3,5460%
- Food & beverage$10,6501%
- Ownership interest$263,70429%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 77 | $770,081 |
| AbbVie(2 entities) | 26 | $29,753 |
| Regeneron Healthcare Solutions, Inc. | 15 | $22,077 |
| Regeneron | 5 | $20,570 |
| Novartis | 15 | $11,329 |
| Alcon Research LLC | 3 | $11,040 |
| Apellis Pharmaceuticals, Inc. | 10 | $9,291 |
| F. Hoffmann-la Roche AG | 6 | $9,245 |
| Genentech USA, Inc. | 3 | $4,835 |
| Alcon | 12 | $2,184 |
| Alimera Sciences, Inc. | 9 | $1,916 |
| Bausch & Lomb Americas Inc. | 9 | $1,437 |
| Astellas Pharma US Inc | 7 | $495 |
| Eyepoint US, Inc. | 3 | $340 |
| Carl Zeiss Meditec USA, Inc. | 2 | $241 |
| Dutch Ophthalmic, USA | 1 | $175 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $122 |
| Carl Zeiss Meditec, Inc. | 2 | $102 |
| Genentech, Inc. | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$253,921
- EYLEA$39,350
- Lucentis$14,080
- OZURDEX$10,500
- DUREZOL$6,204
- Syfovre$4,468
- BEOVU$4,419
- EYLEA HD$2,884
- Iluvien$1,698
- XIPERE$1,000
- Constellation$958
- YUTIQ$404
- ARTEVO 800$220
- EVA, combined machine$175
- TISSUEBLUE$175
- Izervay$122
- STELLARIS$117
- DEXYCU$110
How this compares
$895,275 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 43 | $3,485 |
| Prednisolone Acetate | 37 | $1,680 |
| Ketorolac Tromethamine | 25 | $238 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $218 |
| Latanoprost | 21 | $184 |
| Timolol Maleate | 14 | $137 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Los Angeles
- Barry SeibelLos Angeles$835K
- Nicole FramLos Angeles$551K
- Neda ShamieLos Angeles$547K
- David BoyerLos Angeles$406K
- David HamiltonLos Angeles$359K
- Arjan HuraLos Angeles$306K
- Firas RahhalLos Angeles$264K
- Kouros NourimahdaviLos Angeles$258K
- Daniel RootmanLos Angeles$247K
- Amy JainLos Angeles$233K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.